Phase 1 treatment consisted of a combination of fulvestrant, palbociclib, and everolimus, supported by findings in Bx1 of high ER protein expression, wild-type ESR1, and two intact copies of wild-type RB1. Bx2 was taken when the tumor began to progress on this treatment (Figure 2). The gene discussed is RB1; the disease is neoplasm.